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SUMMARY 
The expression of the nuclear protein p53 in oligodendrogliomas was investigated by immunohistochemistry, 
using a monoclonal anti-p53 antibody (DO-7) on formalin-fixed, paraffin-embedded material in 84 histologically 
verified cases, and compared with the histopathological grade and survival. p53-immunoreactive cells were found in 
75 per cent of the samples acquired at the first biopsy. The p53 labelling index was not related to the degree of 
nuclear anaplasia. Tumour cases with more than 75 per cent p53 immunostained cells had a rapidly fatal clinical 
course. However, no significant correlation was found between p53 labelling index and tumour grade, mitotic index, 
or ploidy status. In most tumour recurrences (n=25) ,  the p53 labelling index increased or remained at the level of the 
first biopsy. In five cases (6 per cent), p53 was absent in the first sample as well as in the recurrence. Irrespective of 
the underlying aberration of either the gene or the metabolic pathway of p53, it is concluded that a high percentage 
(i.e., more than 75 per cent) of p53-immunolabelled cells is predictive of an unfavourable clinical course, while a 
percentage lower than 75 per cent immunoreactive cells does not exclude a rapid fatal outcome. 
KEY woRDs-Ohgodendroglioma, immunohistochemistry, p53, tumour suppressor gene, mitotic index, DNA flow 
cyt ometry . 
INTRODUCTION 
When DNA of normal cells is damaged, the 
nuclear protein p53 is thought to accumulate and 
arrest the cell cycle at G1, presumably in order to 
enable repair of DNA damage.' If p53 is dis- 
rupted, genetically unstable clones could continue 
to divide, resulting in the accumulation of mu- 
tations and chromosomal rearrangements in sub- 
sequent generations.' While in non-neoplastic cells 
p53 expression is almost always below the level of 
immunohistochemical de te~t ion ,~  mutations in 
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the p53 gene or aberrations in p53 degradation 
may result in elevated levels of the p53 protein, 
permitting its immunohistochemical detection. 
Although the connection between disruption of the 
p53 system and development of tumours remains 
speculative, p53 is immunohistochemically detect- 
able in a wide variety of tumours.420 In 
many,4,5,8,9, 12-14,16,18-20 though not a1163731031 5 ~ 1 7  
human cancers, p53 immunoreactivity was found 
to be associated with morphological and cell 
proliferation-related tumour characteristics. 
In astrocytomas, the number of p53 immuno- 
reactive cells reportedly correlated well with 
malignancy Despite the demonstration 
of p53 mutations in oligodendr~gliomas,~~ p53 
immunoreactive cells have been recorded in on1 a 
while no data relating p53 immunohistochemistry 
to tumour grade or clinical course are available. 
The aim of this retrospective study was to inves- 
tigate immunoreactivity for p53 in 84 cases and to 
few cases that have been investigated so far, 21,2l24 
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link the percentages of p53-positive cells with the 
histopathological grades and clinical courses. In 
addition, the data were correlated with the results 
of counting mitoses and DNA flow cytometry 
obtained in a previous study on the same group.26 
MATERIALS AND METHODS 
Clinical records 
The clinical data and formalin-fixed, paraffin- 
embedded material of 111 patients with cerebral 
oligodendrogliomas were taken from the files of 
the University Hospital Rotterdam-Dijkzigt. In 
addition, tissues of ten patients with conditions 
leading to reactive gliosis were processed. The 
same samples of oligodendrogliomas have been 
used earlier in a retrospective study on the impli- 
cations of DNA flow cytograms on the biological 
behaviour of oligodendrogliomas.26 Adequate 
follow-up was obtained in 84 cases. The patients 
had been admitted to the hospital between 1972 
and 1986. The age distribution at the first oper- 
ation showed peaks around 35 and 55 years. 
Craniotomy was performed in order to decom- 
press the brain or debulk the tumour. Patients who 
died within 2 weeks postoperatively were excluded 
from the study, since this short postoperative 
survival was considered as death related to surgical 
complications. Survival times were calculated from 
the date of the first craniotomy. All patients had 
died by the end of the study. 
Grading the oligodendrogliomas and assessing the 
mitotic count 
p53-immunohistochemistry was performed on 
slides adjacent to those used for histopathologi- 
cal grading, DNA flow cytometry, and counting 
mitoses in an earlier study.26 The tumours were 
graded according to the scheme of Smith et 
taking endothelial proliferation, necrosis, nucleus 
to cytoplasm ratio, cell density, and pleomorphism 
into account. The variables were scored in a simple 
present-absent scheme, resulting in the attribution 
of four grades. The scheme has been roven 
to correlate significantly with survival.27, The 
mitotic count was assessed by first selecting the 
highest cell density areas followed by randomly 
choosing fields, and then calculating the quotient 
of the number of mitoses and the total number of 
cells in the fields (objective x 400). The scores 
were grouped into three categories: a category of 
less than one mitosis; a category of more than five 
mitoses; and an intermediate group. 
Y 
Immunohistochemistry 
Immunohistochemistry was performed on 5 pm 
sections. The slides were deparaffinized and en- 
dogenous peroxidase activity was blocked with 3 
per cent hydrogen peroxide (H,O,) in methanol, 
followed by preincubation with 5 per cent normal 
goat serum diluted in phosphate-buffered saline 
and bovine serum albumin (PBS-BSA) for 15 min 
at 37°C. All incubations were performed in a 
humidified chamber. The primary antibody was 
mouse anti-p53 (DO-7), diluted 1:25 in PBS 
overnight at 4°C. DO-7 (Dako, Denmark) was 
raised against recombinant human wild-type p53 
protein expressed in Escherichia coli. This anti- 
body recognizes an epitope in the N-terminus of 
the human p53 protein, residing between amino 
acids 35 and 45, Rinsing the excess antibodies or 
conjugates was done by three 5 min washes in PBS. 
The avidin-biotin-peroxidase complex method 
was used as the detection system. Incubation with 
the biotinylated goat anti-mouse immunoglobulin 
(Dako, Denmark) diluted 1:400 was followed by 
incubation with avidin and biotinylated peroxidase 
complexes (Dako, Denmark) for 30 min at room 
temperature. Final visualization was achieved by 
incubation with 0.02 per cent diaminobenzidine 
(DAB) in PBS and 0.075 per cent H202 for 7 min 
in darkness. As a control, the primary antibody 
was replaced by PBS. The slides were counter- 
stained with haematoxylin. 
Scoring p53-positive cells 
The percentage of p53-positive cells was estab- 
lished by the quotient of the number of p53- 
positive cells and the total number of cells per ten 
fields x 400 magnification using a grid. The counts 
were repeated. The p53 labelling index (LI) was 
defined as 100 x number of labelled nucleietotal 
number of nuclei counted. Five groups were distin- 
guished: a group without positive cells and four 
groups with increasing LI (i.e., 1-25 per cent; 
2 6 5 0  per cent; 51-75 per cent; more than 75 per 
cent). 
Stat is tics 
The statistical tests were performed using the 
Statistical Package for the Social Sciences (SPSSX 
package). Since the frequency distribution of the 
survival times of the patients was exponential, 
e-log transformation was performed in order to 
allow the use of parametric tests. Analysis of 
variance (ANOVA) was used for the detection of 
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Fig. 1-(a) Oligodendroglioma grade B, stained for p53. Clonal patterns of p53-positive cells were not distinguished; p53-positive 
cells were always intermingled with p53-negative cells. (b) Oligodendroglioma grade C, stained for p53. p53 immunoreactivity was 
independent of the degree of nuclear anaplasia 
the main effects of the grading scheme and the 
p53 LI. A posteriori testing was done using the 
Student-Newman-Keuls test with significance at 
the 0.05 level. Dependences between the results of 
p53 immunostaining and those of histopathologi- 
cal grading, DNA flow cytometry, and counting 
mitoses were tested by calculating Cramer’s con- 
tingency coefficient. 
RESULTS 
Control sections of normal brain (grey and 
white matter) and sections of reactive gliosis did 
not contain p53-positive cells. The positive nuclei 
showed a granular staining pattern. Staining was 
always confined to the nucleus and was not seen in 
the cytoplasm of the neoplastic cells (Figs l a  and 
lb). Endothelial cells were always negative for p53, 
even when endothelial proliferation was present. 
Seventy-five per cent of the oligodendrogliomas 
contained p53-positive cells, while 25 per cent of 
the tumours did not have any positive cells (Table 
I). The inter-observer variability was about 5 per 
cent; the intra-observer variability remained below 
2 per cent. The mean survival times for the five 
Table I-Survival times for p53 labelling index (LI) 
Survival time (months) 
p53 LI n Mean SD SEM 
OYO 21 (25%) 34.95 30.48 6.66 
1-25% 23 (27%) 52.83 59.81 12.46 
2650Yo 23 (27Y‘o) 29.61 30.69 6-39 
51-75% 10 (12%) 35.60 28.81 9.12 
>750/0 7 ( W o )  9.29 2.93 1.11 
84 (1 OOYo) 
n=number of patients; mean=mean survival time; 
SD=standard deviation; SEM=standard error of the mean. 
groups based on p53 LI are listed in Table I, and 
the corresponding survival curves are plotted in 
Fig. 2. The curve of the highest p53 LI (i.e., >75 
per cent) falls the fastest, and a significant differ- 
ence between this curve and the curves of tumours 
with a p53 LI of less than 75 per cent was found 
(P<O.OS)(Fig. 2). The mean survival times for the 
four groups distinguished by the grading system 
are listed in Table 11. An increase in tumour grade 
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Fig. 2-Survival curves according to the percentages of p53-positive cells. The curve for p53 
LI between 75 and 100 per cent is clearly separated from the curves for all distinct LI groups 
lower than 75 per cent. Only one high-grade tumour (grade D) was found among the seven 
samples in the >75 per cent curve (Table 111) 
Table 11-Survival times for histopathological grades 
Survival time (months) 
Histopathological 
grades n Mean SD SEM 
A 22 (26%) 56.36 59.98 12.79 
B 41 (49%) 32.77 31.50 4.92 
C 6 (7%) 31.33 30.71 12.53 
D 15 (18%) 17.20 19.72 5.10 
84 (100%) 
See footnote to Table I. 
parallels a decrease in mean survival. The survival 
rates for the two intermediate grades (i.e., grades B 
and C) are virtually indistinguishable. ANOVA 
showed a main effect of the grading system on the 
survival rates (P=0.035). A posteriori testing 
(Student-Newman-Keuls) revealed a significant 
difference between grades A and D at the 0.05 
level. 
Table I11 represents the crosstable between p53 
LI and histopathological grade. No correlation 
between the results of p53 immunostaining and 
histopathological grading was found (Cramer’s 
contingency coefficient =0.444; P=O-194). 
Table 111-Cross-table histopathological grades versus 
p53 LI 
Histopathological grade 
p53 LI A B C D Total 
0 11% 14% 0 4% 290/0 
1-25% 6% 9% 3% 9% 27% 
2650% 5% 14% 10/0 5% 25% 
>75% 0 5% 1% 1% 70/0 
Total 24% 47% 7% 210/0 100% 
51-75% 2% 5% 2% 20/0 11% 
Cramer’s contingency coefficient=0.444; P=0.194. 
Thirty-one per cent of the oligodendrogliomas 
were DNA diploid, 39 per cent had a DNA- 
tetraploid pattern, while 31 per cent were aneu- 
ploid.26 Although the mitotic count correlated with 
the survival time (P<0.0038), the ploidy status did 
not.26 No dependence between the ploidy status of 
the oligodendrogliomas and the p53 LI (CramCr’s 
contingency coefficient=0.323; P=0.527) was 
found. 
In 26 per cent of the tumours, no mitoses within 
3 HPF (high-power fields) were seen. In 57 per cent 
the mitotic count was between 1 and 5,  while in 17 
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Table IV-Cross-table p53 LI in successive biopsies 
( ~ 2 5 )  
p53 expression 
in recurrence 0 1-25% 2650% 51-75% >75% 
p53 expression in primary tumour 
0 5 0  1 0 0 
1-25% 1 4  2 2 0 
2650% 0 0  1 0 0 
5 1-75%0 1 2  2 0 0 
>75% 0 1  2 1 0 
In ten cases the p53 LI was equal in both biopsies, wheras in 
another ten cases the level of demonstrable p53 had increased. 
In five cases the p53 LI in the recurrence was lower than that in 
the initial biopsy, most likely caused by sampling errors. Only 
in two cases was expression of p53 found in the recurrence, 
while the primary tumour was immunonegative. In five cases, 
p53 was demonstrable neither in the primary tumour, nor in the 
recurrence. 
per cent more than five mitoses were counted.26 
No dependence between the mitotic index and 
the p53 LI was found (Cramtr's contingency 
coefficient = 0.282; P=05 10). 
Table IV compares the p53 LI of the first biopsy 
with that of the second biopsy in the 25 patients 
who underwent craniotomy for recurrent tumour. 
In ten cases, no change in the p53 LI was observed 
in the two successive biopsies. In ten cases, an 
increase in p53 expression in the recurrent speci- 
men was seen. In five cases, the p53 LI was lower 
in the second specimen. In two cases, the absence 
of p53 in the primary biopsy was followed by 
demonstrable p53 in the recurrence. In five cases, 
p53 was found in neither the first nor the second 
sample (Table IV). 
DISCUSSION 
The present finding of p53-immunolabelled cells 
in the majority of oligodendrogliomas is compat- 
ible with the findin of mutations in the p53 gene 
in these tumours.2 The low percentages of p53 
immunoreactive cells encountered in oligodendro- 
gliomas reported previously might be explained 
by the small numbers of tumours investi- 
gated.21322,24,29 Th ere are, however, some pitfalls in 
the interpretation of the results of p53 immuno- 
hist~chemistry.~' Negative immunostaining in the 
presence of a mutation might be the result of gross 
deletion abolishing all p53 production or, alterna- 
tively, may imply that the protein product of the 
.F 
mutated gene has remained unstable, and thus un- 
detectable by immunohistochemistry. Positive p53 
immunohistochemistry without a mutation present 
may be due to an interruption of the normal degra- 
dative pathway of p53. In a recent paper on 34 
astrocytomas, comparing the results of p53 im- 
munohistochemistry with those of single-strand 
conformational polymorphism (SSCP), cases of 
either false-negative or false-positive immunohisto- 
chemistry were shown.31 Despite possible discrep- 
ancies between the findings at the DNA level, on 
the one hand, and at the protein level, on the other, 
p53 immunohistochemistry has value for monitor- 
ing the functional status of the protein per se. 
An important finding of this study is that high 
expression of p53 heralds a rapidly fatal clinical 
course. However, low expression of p53 does 
not correspondingly predict a favourable outcome. 
Although an increased percentage of p53-positive 
cells was found in the majority of the recurrences 
(Tables IV), no correlation between p53 expression 
and tumour grade was revealed. In four studies 
mainly concerning astrocytomas, the p53 LI 
reported1 matched histopathological g r a d e ~ . ~ l - ~ ~  
In most+-35 but not studies on glial tu- 
mours, mutations in the p53 gene were associated 
with tumour grade or tumour progress. There is a 
lack of correlation between p53 LI and tumour 
grade in oligodendrogliomas, possibly because of 
defective p53 genes present in low-grade tumours, 
while in high-grade oligodendrogliomas both al- 
leles for the gene might have been lost, resulting in 
negative immunostaining. Alternatively, subsets of 
oligodendrogliomas with genetic defects without 
involvement of p53 might exist: in five cases, p53 
was not found in the primary tumour nor in the 
recurrence. Still, high expression of p53 is predic- 
tive of short survival, irrespective of tumour grade. 
Although in various epithelial neoplasms the 
p53 LI has been linked with a n e ~ p l o i d y , ~ , ~ , ' ~ ~ ~ ~  no 
similar relation was shown in the present study. In 
neoplasms of the lung, the expression of p53 varied 
through the cell cycle and increased with the 
percentage of cells in the S-phase fraction calcu- 
lated from DNA flow cytograms." Controversial 
results concerning p53 expression and proliferation 
markers in glial tumours exist in the literature, 
while data specifically addressing oligodendroglio- 
mas are missing. Jaros et al. found a relation 
between the expression of p53 and the Ki-67 
labelling index in adjacent slides of 43 astro- 
cytomas,21 roughly indicating a link between pro- 
liferation fraction and p53 expression. However, 
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no such correlation was found in a study including 
46 astrocytomas, in which antibodies against pro- 
liferating cell nuclear antigen (PCNA) were used.29 
The mitotic index did not correlate with the p53 LI 
in the oligodendrogliomas studied here. Double- 
labelling techniques using proliferation markers in 
combination with p53 antibody might disclose a 
relation between the expression of mutant p53 and 
the cell cycle phase at the level of the individual 
cell. 
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